Phase IB/II Study of Bazedoxifene in Combination with Palbociclib in Patients with Endocrine Resistant Hormone Receptor-Positive Breast Cancer
Demographics (2)
- AGE_ONSET - Disease onset age (phv00498080.v1.p1)
- SEX - Biological sex (phv00498076.v1.p1)
Other (16)
- ANALYTE_TYPE - Analyte Type (phv00498084.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00498083.v1.p1)
- CLINICAL_BENEFIT - Whether or not clinical benefit was observed (phv00498081.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00498075.v1.p1)
- HISTOLOGICAL_TYPE - Cell or tissue type or subtype of sample (phv00498086.v1.p1)
- PRIMARY_METASTATIC_TUMOR - Primary tumor, metastasis, or transformed cell line (phv00498087.v1.p1)
- PRIMARY_TUMOR_LOCATION - Primary tumor location (phv00498088.v1.p1)
- SAMPLE_ID - Sample ID (phv00498082.v1.p1)
- SAMPLE_ID - Sample ID (phv00498078.v1.p1)
- SAMPLE_TIMEPOINT - Timepoint of sample collection (phv00498085.v1.p1)
- SEQUENCING_CENTER - Center that performed sequencing (phv00498091.v1.p1)
- SUBJECT_ID - Subject ID (phv00498074.v1.p1)
- SUBJECT_ID - Subject ID (phv00498079.v1.p1)
- SUBJECT_ID - Subject ID (phv00498077.v1.p1)
- TUMOR_STAGE - Tumor stage of sample (phv00498089.v1.p1)
- TUMOR_TREATMENT - Type of tumor treatment for sample (phv00498090.v1.p1)